Bioventix PLC (AIM:BVXP)

Market Cap	156.59M
Revenue (ttm)	13.61M
Net Income (ttm)	8.10M
Shares Out	5.22M
EPS (ttm)	1.53
PE Ratio	19.63
Forward PE	17.54
Dividend	1.55 (5.17%)
Ex-Dividend Date	Nov 7, 2024

Volume	6,762
Average Volume	5,217
Open	2,920.00
Previous Close	3,000.00
Day's Range	2,900.00 - 3,040.00
52-Week Range	2,700.00 - 5,100.00
Beta	0.44
RSI	46.02
Earnings Date	Mar 25, 2025

About Bioventix

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. It also provides contract SMAs services; and industrial and environ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 17
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: BVXP

Financial Performance

In 2024, Bioventix's revenue was 13.61 million, an increase of 6.17% compared to the previous year's 12.82 million. Earnings were 8.10 million, a decrease of -3.29%.